$35.56
0.08% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US52490G1022
Symbol
LEGN

Legend Biotech Corp - ADR Stock price

$35.56
-8.46 19.22% 1M
-1.42 3.84% 6M
+3.02 9.28% YTD
-21.82 38.03% 1Y
-9.74 21.50% 3Y
+0.50 1.43% 5Y
-1.44 3.89% 10Y
-1.44 3.89% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.03 0.08%
ISIN
US52490G1022
Symbol
LEGN
Industry

Key metrics

Basic
Market capitalization
$6.6b
Enterprise Value
$6.0b
Net debt
positive
Cash
$967.6m
Shares outstanding
369.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.2 | 6.3
EV/Sales
7.5 | 5.7
EV/FCF
negative
P/B
6.3
Financial Health
Equity Ratio
62.3%
Return on Equity
-17.0%
ROCE
-15.3%
ROIC
-50.3%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$796.8m | $1.0b
EBITDA
$-194.5m | $-124.6m
EBIT
$-217.8m | $-136.1m
Net Income
$-325.3m | $-211.4m
Free Cash Flow
$-290.4m
Growth (TTM | estimate)
Revenue
74.8% | 66.8%
EBITDA
44.7% | 55.8%
EBIT
41.7% | 55.4%
Net Income
-14.1% | -19.4%
Free Cash Flow
-76.4%
Margin (TTM | estimate)
Gross
62.5%
EBITDA
-24.4% | -11.9%
EBIT
-27.3%
Net
-40.8% | -20.2%
Free Cash Flow
-36.4%
More
EPS
$-0.9
FCF per Share
$-0.8
Short interest
8.2%
Employees
3k
Rev per Employee
$240.0k
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Legend Biotech Corp - ADR forecast:

26x Buy
93%
2x Hold
7%

Analyst Opinions

28 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
93%
Hold
7%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
797 797
75% 75%
100%
- Direct Costs 299 299
65% 65%
37%
498 498
81% 81%
63%
- Selling and Administrative Expenses 316 316
35% 35%
40%
- Research and Development Expense 400 400
4% 4%
50%
-195 -195
45% 45%
-24%
- Depreciation and Amortization 23 23
8% 8%
3%
EBIT (Operating Income) EBIT -218 -218
42% 42%
-27%
Net Profit -325 -325
14% 14%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Neutral
GlobeNewsWire
6 days ago
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.
Neutral
Seeking Alpha
8 days ago
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Neutral
Seeking Alpha
10 days ago
New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue share outside China. Despite >$1bn cash and operational improvements, Legend remains unprofitable, wi...
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 2,600
Founded 2014
Website investors.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today